Tivozanib
4 clinical trials
2 products
3 abstracts
13 indications
1 target
Indication
Bile Duct CancerIndication
Gallbladder CancerIndication
Breast CancerIndication
Neuroendocrine TumorsIndication
Ovarian CancerIndication
Pancreatic adenocarcinomaIndication
Soft Tissue SarcomaIndication
Vulvar CancerIndication
Prostate CancerIndication
CholangiocarcinomaIndication
Bile Duct NeoplasmIndication
Biliary Tract MalignancyIndication
Renal Cell CarcinomaClinical trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesStatus: Recruiting, Estimated PCD: 2024-12-01
Abstract
Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial.Org: Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI,
Clinical trial
Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-11-01
Abstract
The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre.Org: Hull University Teaching Hospitals NHS Trust, University of Leeds, Royal Cornwall Hospital NHS Trust,
Abstract
T-Rex study: Quality of life assessment using novel CTCAE-PRO and FKSI-19 in first-line treatment of metastatic renal cell carcinoma with tivozanib.Org: Essen University Hospital, West German Cancer Center, University Hospital Essen, Clinic for Medical Oncology & Clinic for Urology, Urologisch-onkol. Schwerpunktpraxis Bernburg, Praxisnetzwerk Hämatologie und internistische Onkologie,
Product
TivozanibProduct
targeted therapies